Healthcare
Teledoc: Time to Collect$TDOC, Cathie Wood's 3rd largest position (ARK Investing) has dropped more than 31% from its ATH retracing down to its 200SMA on the daily chart. This is is a great company with great future potentials. The price may drop further due to an overall sell-off in the entire market, which gives us a better opportunity to collect more. Not financial advice, DYODD!
CLOV - There's absolutely NO SHOT..... right?Alright, so hear me out.
NASDAQ:CLOV has this insane, speculative expanding wedge/triangle pattern forming. I mean, there's absolutely NO SHOT this can actually play out. It HAS to be just a coincidence...... right?
The featured content is intended to be used for informational purposes only. Everything shared here is my own opinion. It is very important to do your own analysis before making any investment based on your own personal circumstances.
VMD is breakout NASDAQ:VMD is breaking out nicely, targets are shown on the chart. This is a long trade and the stock is a good to hold for long term. Stop loss around 7.3$.
Hit the like button and follow if you find this useful :)
This is only my own view and not financial advice, do your own analysis before buying or selling
Happy Trading!
GoHealth formed head and shoulder and double bottom patternNASDAQ:GOCO broke out of the double bottom pattern and retested the neck line and is now about to break out of the head and shoulders pattern. Targets are shown on the chart, stop ideally at 11.6$.
Hit the like button and follow if you find this useful :)
This is only my own view and not financial advice, do your own analysis before buying or selling
Happy Trading!
OcugenOcugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
I might've marked this up a few weeks ago. However, here is an updated outlook after hearing some positive news from its camp that was released today.
What do you think?
Like, Follow, Agree, Disagree!
Details in photo!
Strike price $12.12
EDIT Genome Editing Long-Term SwingEDIT NASDAQ:EDIT is a genome editing company with treatments being developed for Leber congenital amaurosis**, Usher syndrome, neurological diseases, Sickle cell disease, beta-thalassemia, as well as cancer treatments through NK cells. The leber congenital amaurosis clinical trial is currently the furthest along but still in its earlier stages but has completed dosing all of its patients. The results of that clinical trial will be HUGE. That will set the blueprint for EDIT as a company. The same principles for that EDIT-101 clinical trial are being applied to multiple other medicines and can lay the blueprint for huge medical breakthroughs. ARK believes genome editing is the future of medicine and I agree. This 46% sell off since EDIT’s highs looks to be a strong bounce area. I grabbed a small starter position on Friday last week but will look to add to my position this week and add dips to $50. If we fail $50.48 HVN area I will use that as my stop.
Chart:
EDIT looks to be in a prime bounce zone right now and I will be looking for it to hold the HVN area ($57-$66) for some consolidation. Daily .618 fib retracement line has served as support multiple times and will want that to hold up this week. Need some volume to being accumulating on EDIT and close back over the $58 lvl.
Flag forming in Gold. $2,200 possible within the yearGold has been consolidating and retracting in volume. It looks coiled to break-out past previous resistance. The 50,100, and 200-day moving averages are on the verge of intersecting and hopefully reversing course in a more bullish direction.
Signal to buy should be when shorter-term MA's breakthrough 200-day.
RSI, MACD, and Gold spot prices have been declining in unison. RSI signals it is not overbought and MACD is signaling buy which gives this trade some legs and breathing room.
On the fundamental side, gold is the most resistant to rust and corrosion, making it the most reliable and durable electrical conductor. It is key for computer and satellite technology. If Starlink is going to become a reality, regardless of whether or not it does so under the umbrella of Tesla or by IPO'ing, they will need a lot of gold to make those satellites low maintenance.
Gold is also essential in the production of green technology and it is essential for healthcare and our digital world.
I expect spot prices of $2,200 within the year and at least $2,500 by 2022.
$CLOV Stick to the PlanTrue longs are staying patient, even with the volatile week we've experienced thus far.
$CLOV is attempting to make a presence within the healthcare industry, which is never an easy path. Their mission as a company will be very difficult to pursue, although a very lucrative one if executed adequately.
With a Biden Administration advocating health care for all in America, the push from various lawmakers in congress will help aid individuals gain access to companies like Clover, who are offering insurance at very little-to-none premiums, copays, and prescription drug prices.
I will be updating this post as I have entered a multi-week swing, which may turn into a long-term hold- depending on confirmation within the price action. GLTA!
FMS Technical Analysis 🧙Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients in roughly 4,000 clinics across the globe as of December 2019. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly
If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
$ZOM could surge 100% due to upcoming launch of TruformaTangible catalyst behind surge is due to the upcoming launch of Truforma , Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs.
The platform will hit the market on March 30 , and ahead of the product’s debut, the company has also just nabbed a vital distribution deal.
Last week, Zomedica announced an agreement with Miller Veterinary Supply who will distribute Truforma.
Miller is the U.S.’s oldest wholesale veterinary distributor and one of the veterinary industry’s fastest growing businesses. The company will be Zomedica’s representative in the eastern and mid-eastern states. Its sales and customer service efforts will be bolstered by sales representatives assigned by Zomedica, which the company is currently recruiting as it prepares for the launch.
The pet market has been a prime beneficiary of the pandemic’s stay-at-home mandates and according to the American Pet Products Association, spending in the segment reached a record $99 billion in the U.S. last year. Outlay on diagnostic care in this market is expected to grow to $2.8 billion in 2024 from $1.7 billion in 2019.
H.C. Wainwright analyst Swayampakula Ramakanth says that ahead of Truforma’s debut, the agreement “strengthens the commercial machinery.”
“We are encouraged by the progress in commercial preparation for the upcoming launch, and accordingly we are raising the probability of launch to 90%, up from 75% previously,” the 5-star analyst said. “Additionally, due to the lower yield of the long-term Treasury note that has resulted in a lower risk-free rate and a lower market risk premium, we have adjusted the discount rate to 6% from 12%.”
To this end, Ramakanth boosted his price target on ZOM from $0.3 to $1.2, suggesting upside of an additional 20% from current levels. Needless to say, Ramakanth’s rating stays a Buy.
finance.yahoo.com
$CLOV Bearish Channels Breakout upward Incoming$CLOV was consolidating after a retracement down. After consolidation and approaching the edge of a wedge indicating a big movement. They were unexpectedly the target of a short sellers report which caused the movement to continue downward. With a well articulated rebuttal the doc was able to rally and bounce back up. We appear to be at the bottom of a bearish channel and will likely retrace back up in the near future a short squeeze caused by any positive catalyst will likely break the channel upward allowing us to retrace upward towards the $14 area. With February 19th options expiring I expect the retracement to happen soon after.
Bottom-fishing for long-term trading.According to Wells Fargo Advisors, "BAX: OMCL Would Be An Excellent Fit ... OMCL would bring better IT integration and an expanded set of hospital relationships as Baxter launches a new infusion pump next year. OMCL might also be able to finally realize its vision of a stronger international business (9% of total revenue) with the help of Baxter’s infrastructure. The pandemic pressured OMCL’s original 13% revenue growth target for 2020 down to a 2% revenue decline. However, management indicated bookings surged so much in Q3 the company was able to reinstate its original 9% bookings growth guidance for 2020 and gave a 2021 revenue outlook of 17% growth (13% organic). So, fundamentals seem solid."
Genisi bull flag break (12 hr)Upward momentum on the StochRSI, RSI trending up ,recent break of 12 hr bull flag ...Target 89/90 (depending on StochRSI peaking)
MMEDF over 3.41OTC name in the cutting-edge field of medical psilocybin is back in the consolidation zone. Can accumulate shares here or wait for the breakout confirmation to play to recent highs.
WARNING! The biggest short seller of is “Goldman Sachs Hedge Industry VIP ETF” and I don’t know the other ones. But this one for example holds a lot of healthcare stocks (for example Change Healthcare Inc CHNG). So by buying GME some healthcare stocks, paypal, apple... etc. get at least under pressure. And a lot of stuff is invested in this etf. I couldn’t do the full research but higher prices in GME could destroy your saving on the bank or life insurances or… so nobody knows who really wins with higher prices. Maybe somebody can research that who really is losing here Please, before everything is to late. Maybe this was even on purpose to get rid of unpaid bill to the “regular” people. This ETF goes bankrupt and all the invested Money in this etf is gone! Can someone please make a full research! I wasn’t able to find it!
Swing Trade: 🏥 Healtcare sector: Vapo BreakoutHi guys,
Sharing one of my today swingtrades in healtcare.
Nice setup for breakout.
If you like the idea, do not forget to support with a 👍 like and follow.
Leave a comment that is helpful or encouraging. Let's master the markets together.
Trade Alert pt.2: NVIVGap fill in progress, we have a runner here.
Should look to fill gap to $5 BUT it might fall short. Either way this is already running and passed the "magic $1" so should be multi day runner. Time will tell.
PT 1: $2 PT2: $4.60
Loss exit on pullback under 1.40
If this drops to red box zone its bad news, though Looks less likely to go down based on chart
Good luck!
Previous post on NVIV below:
*Please leave a like if you find this helpful!*
MYCO - Next Move? MYCO has formed a prefect cup & handle on the daily
- 4 hits against an important 0.60 resistance
- handle dropped perfectly on the 0.5 fib support level
- price is currently consolidating right below resistance
Fundamentals in the psychedelic space are lining up perfectly for a MYCO breakout.
- they are 1 in only 4 companies currently approved for phase 2 FDA trials
- confirmed listing on the first ever psychedelic ETF - PSYK
However, a breakout will only be confirmed after a daily close above 0.60 - volume and a newly approved catalyst will be key
Good Luck to All!
CLOV over 14.55Nice confluence here where the .618 fib from all time low to high should make a nice entry.
DNA ReconstructionAlright team i want you to keep this channel in mind as we progress through another Green Week!
I am predicting this price will maintain within this channel moving forward.
As you can see now it is doing a good job staying within !
Penny stocks are always volatile. However The revolutionary technology this company is bringing to the table is outstanding
I am sure a lot of you already researched it and know this ! so i wont get into it.
Keep in mind Buy low & NEVER SELL!
Follow me for technical analysis!
All of this is only opinion and my own personal journal.
None of this is financial advice !
& if you dont plan on holding long term. Dont bother putting your money in this market.
